Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Related Stories

alt_text

Thursday, Apr 2 2020

Director of Hadassah Hospital Ein Kerem Appears on CNN

Prof. Yoram Weiss, Director of Hadassah HospitalEin Kerem, was recently interviewed on CNN.

READ MORE ›
alt_text

Tuesday, Mar 31 2020

Together During COVID-19: Prof. Allon Moses on JBS-TV

Interviewed via Skype by Rabbi Mark Golub of the Jewish Broadcasting Service, Prof. Alon Moses...

READ MORE ›
alt_text

Monday, Mar 30 2020

Building Intensive Care Capacity for COVID-19 Patients at Hadassah

Addressing over 125 Hadassah supporters, Prof. Sigal Sviri, the Hadassah Medical Organization’s director of intensive care, told webinar participants...

READ MORE ›
alt_text

Monday, Mar 30 2020

Despite COVID-19, Hadassah Convoy’s Fallen Are Not Forgotten

Hadassah Medical Organization staff, Israeli dignitaries, and the families of those murdered were scheduled to gather Sunday, the fourth day of the Hebrew month of Nissan

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More